Clearmind Medicine (CMND) announced the filing of an Israeli patent application for its combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, addressing depression. The patent application stems from Clearmind’s collaboration with Neurothera Labs, a subsidiary of SciSparc (SPRC). This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280M people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Atai Beckley, Cybin report quarterly earnings
- Clearmind Medicine receives final approval to expand Phase 1/2a AUD trial
- Clearmind announces notice of publication of patent for MEAI in China
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Psychedelic: Compass Pathways, GH Research report Q3 earnings